The Effect of Recombinant Activated Factor VII on Mortality in Combat-Related Casualties With Severe Trauma and Massive Transfusion
Abstract
Background: The majority of patients with potentially survivable combat-related injuries die from hemorrhage. Our objective was to determine whether the use of recombinant activated factor VII (rFVIIa) decreased mortality in combat casualties with severe trauma who received massive transfusions and if its use was associated with increased severe thrombotic events. Methods: We retrospectively reviewed a database of combat casualty patients with severe trauma (Injury Severity Score [ISS] >15) and massive transfusion (red blood cell [RBCs] >10 units/24 hours) admitted to one combat support hospital in Baghdad, Iraq, between December 2003 and October 2005. Admission vital signs and laboratory data, blood products, ISS, 24-hour and 30-day mortality, and severe thrombotic events were compared between patients who received rFVIIa (rFVIIa+) and did not receive rFVIIa (rFVIIa-). Conclusions: The early use of rFVIIa was associated with decreased 30- mortality in severely injured combat casualties requiring massive transfusion, was not associated with increased risk severe thrombotic events.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2008
- Accession Number
- ADA480377
Entities
People
- Alec C. Beekley
- Charles E Wade
- Daniel F. Mclaughlin
- Jeremy G. Perkins
- John B Holcomb
- Josè Salinas
- Kurt W. Grathwohl
- Philip C Spinella
- Sarah E. Niles
- Sumeru Mehta
Organizations
- United States Army Institute of Surgical Research